Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
3sbio
About
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing.
- Shenyang,Liaoning,China
- 501 - 1000
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- Fr15M
- Industries
- Biotechnology
- Founded date
- Jan 1, 1993
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
- Stock Symbol
- hkg:1530
- Legal Name
- Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd.
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 12, 2019 | Post-IPO Equity | Fr15M | 1 |
Numab
|
— | Detail |
| Jun 12, 2015 | IPO | — | — | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 20, 2019
GenSight Biologics
|
Post-IPO Debt | €15M | Biotechnology | — |
|
Dec 12, 2019
Numab
|
Series B | Fr22M | Biopharma | — |
|
Oct 21, 2019
Verseau Therapeutics
|
Series Unknown | $50M | Biotechnology | — |
|
May 2, 2018
Refuge Biotechnologies
|
Series B | $25M | Biotechnology | Yes |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Numab
|
Yes | Post-IPO Equity |
Employee Profiles
Exits
3sbio has had 1 exits. 3sbio most notable exits include GenSight Biologics
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Jul 15, 2016 | GenSight Biologics | IPO | Biotechnology | Detail |
Acquisition
3sbio has acquired 3 organizations. Their most recent acquisition was Sirton Pharmaceuticals on Jan 26, 2015. They acquired Sirton Pharmaceuticals for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jan 26, 2015
Sirton Pharmaceuticals
|
Manufacturing | acquisition | — | Detail |
|
Jul 24, 2015
|
Biotechnology | acquisition | $ 85M | Detail |
|
Sep 3, 2017
Therapure Biopharma
|
Manufacturing | acquisition | $ 290M | Detail |
